BCTXLBriaCell Therapeutics Corp. Warrant expiring 2031

1.090USDMkt Cap: —P/E: —3d ago

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against…

Key Statistics

Company

Market Cap—

Enterprise Value—

Revenue (TTM)—

Gross Profit—

Net Income (TTM)-30.68M $

Revenue/Share—

Last Price1.090 USD

Fiscal Year End—

MR Quarter—

Employees—

CountryUS

Sector—

Industry—

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA—

EV/Revenue—

P/S—

P/B0.33

EPS (TTM)—

EPS (Forward)—

52W Range

0.995083% of range1.110

52W High1.110 USD

52W Low0.9950 USD

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-175.25%

ROA-90.84%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-30.82M $

CapEx (TTM)—

FCF Margin—

FCF Yield—

Net Debt-22.80M $

Net Debt/EBITDA0.71

Balance Sheet

Debt/Equity—

Current Ratio7.07

Quick Ratio6.35

Book Value/Sh3.318 USD

Cash/Share2.621 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.0000 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.—

Float7.86M

Insiders—

Institutions—

Technical

SMA 50—

SMA 200—

Beta1.52

S&P 52W Chg19.18%

Avg Vol (30d)35.56K

Avg Vol (10d)—

Technical Indicators

RSI (14)—

MACD—

MACD Signal—

MACD Hist.—

BB Upper—

BB Middle—

BB Lower—

BB Width—

ATR (14)—

Vol Ratio (20d)—